Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy.

Brines M, Culver DA, Ferdousi M, Tannemaat MR, van Velzen M, Dahan A, Malik RA.

Sci Rep. 2018 Mar 16;8(1):4734. doi: 10.1038/s41598-018-23107-w.

2.

Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.

Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, Arcoraci V, Aliquò F, Minutoli L, Colonna MR, Galeano MR, Brines M, De Ponte C, Collino M, Squadrito F, Altavilla D.

Biochim Biophys Acta. 2018 Feb;1864(2):632-639. doi: 10.1016/j.bbadis.2017.12.006. Epub 2017 Dec 7.

PMID:
29223734
3.

Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.

Nairz M, Haschka D, Dichtl S, Sonnweber T, Schroll A, Aßhoff M, Mindur JE, Moser PL, Wolf D, Swirski FK, Theurl I, Cerami A, Brines M, Weiss G.

Sci Rep. 2017 Oct 12;7(1):13012. doi: 10.1038/s41598-017-13046-3.

4.

Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsies.

Oudejans LC, Niesters M, Brines M, Dahan A, van Velzen M.

J Pain Res. 2017 Aug 26;10:2057-2065. doi: 10.2147/JPR.S142683. eCollection 2017.

5.

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO52-BIO60. doi: 10.1167/iovs.16-21291.

PMID:
28475703
6.

Targeting the innate repair receptor to treat neuropathy.

Dahan A, Brines M, Niesters M, Cerami A, van Velzen M.

Pain Rep. 2016 Aug 9;1(1):e566. doi: 10.1097/PR9.0000000000000566. eCollection 2016 Jul.

7.

ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.

Hache G, Garrigue P, Bennis Y, Stalin J, Moyon A, Cerami A, Brines M, Blot-Chabaud M, Sabatier F, Dignat-George F, Guillet B.

Shock. 2016 Oct;46(4):390-7. doi: 10.1097/SHK.0000000000000606.

PMID:
27172159
8.

Cornea nerve fiber quantification and construction of phenotypes in patients with fibromyalgia.

Oudejans L, He X, Niesters M, Dahan A, Brines M, van Velzen M.

Sci Rep. 2016 Mar 23;6:23573. doi: 10.1038/srep23573.

9.

ARA290 improves insulin release and glucose tolerance in type 2 diabetic GK rats.

Muller C, Yassin K, Li LS, Palmblad M, Efendic S, Berggren PO, Cerami A, Brines M, Östenson CG.

Mol Med. 2015 Dec 29. doi: 10.2119/molmed.2015.00267. [Epub ahead of print]

10.

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.

Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Kumagai-Braesch M.

Transplantation. 2016 Mar;100(3):554-62. doi: 10.1097/TP.0000000000001026.

PMID:
26683514
11.

Urban air quality comparison for bus, tram, subway and pedestrian commutes in Barcelona.

Moreno T, Reche C, Rivas I, Cruz Minguillón M, Martins V, Vargas C, Buonanno G, Parga J, Pandolfi M, Brines M, Ealo M, Sofia Fonseca A, Amato F, Sosa G, Capdevila M, de Miguel E, Querol X, Gibbons W.

Environ Res. 2015 Oct;142:495-510. doi: 10.1016/j.envres.2015.07.022. Epub 2015 Aug 13.

12.

Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.

Collino M, Thiemermann C, Cerami A, Brines M.

Pharmacol Ther. 2015 Jul;151:32-40. doi: 10.1016/j.pharmthera.2015.02.005. Epub 2015 Feb 26. Review.

13.

Determinants of aerosol lung-deposited surface area variation in an urban environment.

Reche C, Viana M, Brines M, Pérez N, Beddows D, Alastuey A, Querol X.

Sci Total Environ. 2015 Jun 1;517:38-47. doi: 10.1016/j.scitotenv.2015.02.049. Epub 2015 Feb 21.

PMID:
25710624
14.

Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair.

Brines M.

Mol Med. 2014 Dec 16;20 Suppl 1:S10-6. doi: 10.2119/molmed.2014.00167.

15.

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A.

Mol Med. 2015 Mar 13;20:658-66. doi: 10.2119/molmed.2014.00215.

16.

Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.

Bohr S, Patel SJ, Vasko R, Shen K, Iracheta-Vellve A, Lee J, Bale SS, Chakraborty N, Brines M, Cerami A, Berthiaume F, Yarmush ML.

J Mol Med (Berl). 2015 Feb;93(2):199-210. doi: 10.1007/s00109-014-1218-2. Epub 2014 Nov 6.

17.

The mast cell plays a central role in the immune system of teleost fish.

Sfacteria A, Brines M, Blank U.

Mol Immunol. 2015 Jan;63(1):3-8. doi: 10.1016/j.molimm.2014.02.007. Epub 2014 Mar 7. Review. Erratum in: Mol Immunol. 2015 Oct;67(2 Pt B):668.

PMID:
24613788
18.

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M.

Expert Opin Investig Drugs. 2014 Apr;23(4):541-50. doi: 10.1517/13543784.2014.892072. Epub 2014 Feb 21. Review.

PMID:
24555851
19.

ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.

Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A.

Mol Pain. 2014 Feb 16;10:13. doi: 10.1186/1744-8069-10-13.

20.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M.

Mol Med. 2013 Nov 8;19:334-45. doi: 10.2119/molmed.2013.00122. Erratum in: Mol Med. 2016 Oct 20;22:674.

21.

Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).

Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Hand CC, Kim HS, Brines M, Cerami A, Dahan A.

PLoS One. 2013 Aug 1;8(8):e71326. doi: 10.1371/journal.pone.0071326. Print 2013.

22.

Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

Ueba H, Shiomi M, Brines M, Yamin M, Kobayashi T, Ako J, Momomura S, Cerami A, Kawakami M.

Mol Med. 2013 Jul 24;19:195-202. doi: 10.2119/molmed.2013.00037.

23.

Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor.

Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C.

Kidney Int. 2013 Sep;84(3):482-90. doi: 10.1038/ki.2013.118. Epub 2013 Apr 17.

24.

Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.

Ahmet I, Tae HJ, Brines M, Cerami A, Lakatta EG, Talan MI.

J Pharmacol Exp Ther. 2013 Jun;345(3):446-56. doi: 10.1124/jpet.113.202945. Epub 2013 Apr 12.

25.

Erythropoietin and engineered innate repair activators.

Brines M, Cerami A.

Methods Mol Biol. 2013;982:1-11. doi: 10.1007/978-1-62703-308-4_1.

PMID:
23456859
26.

Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns.

Bohr S, Patel SJ, Shen K, Vitalo AG, Brines M, Cerami A, Berthiaume F, Yarmush ML.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3513-8. doi: 10.1073/pnas.1214099110. Epub 2013 Feb 11.

27.

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A.

Mol Med. 2012 Nov 15;18:1430-6. doi: 10.2119/molmed.2012.00332.

28.

Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C.

Mol Med. 2012 May 9;18:719-27. doi: 10.2119/molmed.2012.00093.

29.

The receptor that tames the innate immune response.

Brines M, Cerami A.

Mol Med. 2012 May 9;18:486-96. doi: 10.2119/molmed.2011.00414. Review.

30.

Anthropometric variables accurately predict dual energy x-ray absorptiometric-derived body composition and can be used to screen for diabetes.

Yavari R, McEntee E, McEntee M, Brines M.

PLoS One. 2011;6(9):e24017. doi: 10.1371/journal.pone.0024017. Epub 2011 Sep 6.

31.

Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.

McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, Cerami A, Stitt AW.

Diabetes. 2011 Nov;60(11):2995-3005. doi: 10.2337/db11-0026. Epub 2011 Sep 12.

32.

ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.

Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A.

Anesthesiology. 2011 Nov;115(5):1084-92. doi: 10.1097/ALN.0b013e31822fcefd.

PMID:
21873879
33.

Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.

Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Yamin M, Brines M.

Exp Neurol. 2011 Dec;232(2):126-35. doi: 10.1016/j.expneurol.2011.05.025. Epub 2011 Aug 18.

34.

A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

Patel NS, Nandra KK, Brines M, Collino M, Wong WF, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiemermann C.

Mol Med. 2011 Sep-Oct;17(9-10):883-92. doi: 10.2119/molmed.2011.00053. Epub 2011 May 13.

35.

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI.

Mol Med. 2011 Mar-Apr;17(3-4):194-200. doi: 10.2119/molmed.2010.00235. Epub 2010 Dec 16.

36.

Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Hand CC, Brines M.

J Investig Med. 2011 Oct;59(7):1073-82. doi: 10.2310/JIM.0b013e3181ed30bf. Review.

37.

Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin.

Ueba H, Brines M, Yamin M, Umemoto T, Ako J, Momomura S, Cerami A, Kawakami M.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14357-62. doi: 10.1073/pnas.1003019107. Epub 2010 Jul 26.

38.

Erythropoietin: not just about erythropoiesis.

Ghezzi P, Bernaudin M, Bianchi R, Blomgren K, Brines M, Campana W, Cavaletti G, Cerami A, Chopp M, Coleman T, Digicaylioglu M, Ehrenreich H, Erbayraktar S, Erbayraktar Z, Gassmann M, Genc S, Gokmen N, Grasso G, Juul S, Lipton SA, Hand CC, Latini R, Lauria G, Leist M, Newton SS, Petit E, Probert L, Sfacteria A, Siren AL, Talan M, Thiemermann C, Westenbrink D, Yaqoob M, Zhu C.

Lancet. 2010 Jun 19;375(9732):2142. doi: 10.1016/S0140-6736(10)60992-0. No abstract available. Erratum in: Lancet. 2010 Aug 7;376(9739):418. Bernaudinb, Myriam [corrected to Bernaudin, Myrian]; Bianchic, Roberto [corrected to Bianchi, Roberto].

39.

The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors.

Brines M.

Blood Purif. 2010;29(2):86-92. doi: 10.1159/000245630. Epub 2010 Jan 8. Review.

PMID:
20093809
40.

Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.

Erbayraktar Z, Erbayraktar S, Yilmaz O, Cerami A, Coleman T, Brines M.

Mol Med. 2009 Jul-Aug;15(7-8):235-41. doi: 10.2119/molmed.2009.00051. Epub 2009 Apr 16.

41.

Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection.

Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, Cerami A, Andersson U, Zelenina M, Aperia A.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1602-7. doi: 10.1073/pnas.0812708106. Epub 2009 Jan 21.

42.

Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response.

Brines M, Cerami A.

J Intern Med. 2008 Nov;264(5):405-32. doi: 10.1111/j.1365-2796.2008.02024.x. Review.

43.

Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30. doi: 10.1073/pnas.0805594105. Epub 2008 Aug 1.

44.

TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury.

Taoufik E, Petit E, Divoux D, Tseveleki V, Mengozzi M, Roberts ML, Valable S, Ghezzi P, Quackenbush J, Brines M, Cerami A, Probert L.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6185-90. doi: 10.1073/pnas.0801447105. Epub 2008 Apr 14.

45.

Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?

Latini R, Brines M, Fiordaliso F.

Heart Fail Rev. 2008 Dec;13(4):415-23. doi: 10.1007/s10741-008-9084-z. Epub 2008 Jan 31. Review.

PMID:
18236153
46.

Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Schmidt RE, Green KG, Feng D, Dorsey DA, Parvin CA, Lee JM, Xiao Q, Brines M.

Exp Neurol. 2008 Jan;209(1):161-70. Epub 2007 Oct 29.

47.

Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia.

Fantacci M, Bianciardi P, Caretti A, Coleman TR, Cerami A, Brines M, Samaja M.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17531-6. Epub 2006 Nov 7.

48.

Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo.

Mennini T, De Paola M, Bigini P, Mastrotto C, Fumagalli E, Barbera S, Mengozzi M, Viviani B, Corsini E, Marinovich M, Torup L, Van Beek J, Leist M, Brines M, Cerami A, Ghezzi P.

Mol Med. 2006 Jul-Aug;12(7-8):153-60.

49.

Carbamylated erythropoietin reduces radiosurgically-induced brain injury.

Erbayraktar S, de Lanerolle N, de Lotbinière A, Knisely JP, Erbayraktar Z, Yilmaz O, Cerami A, Coleman TR, Brines M.

Mol Med. 2006 Apr-Jun;12(4-6):74-80.

50.

Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.

Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L.

J Cereb Blood Flow Metab. 2007 Mar;27(3):552-63. Epub 2006 Jul 12.

PMID:
16835629

Supplemental Content

Loading ...
Support Center